Carfilzomib-d8 – 500 µg

Brand:
Cayman
CAS:
1537187-53-3
Storage:
-20
UN-No:
Non-Hazardous - /

Carfilzomib-d8 is intended for use as an internal standard for the quantification of carfilzomib (Item No. 17554) by GC- or LC-MS. Carfilzomib is an irreversible proteosome inhibitor classified as a peptide epoxyketone. It targets the chymotrypsin-like β5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the β5i subunit of the immunoproteasome 20Si (LMP7; IC50 = 14 nM) with minimal cross reactivity to other proteases.{28244,28242} It can induce cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma, and various solid tumors (IC50s = 2.4-20 nM).{25593,28537}  

 

Out of stock

SKU: 22558 - Category:

Description

An internal standard for the quantification of carfilzomib by GC- or LC-MS,


Formal name: (αS)-α-[[2-(4-morpholinyl-2,2,3,3,5,5,6,6-d8)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide

Synonyms: 

Molecular weight: 728

CAS: 1537187-53-3

Purity: ≥99% deuterated forms (d1-d8)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cell Biology|Proteolysis|Ubiquitin/Proteasome System